November 18, 2024 Acuitas Scientists Highlight Next Generation LNP Technology at International mRNA Health Conference Read about Acuitas Scientists Highlight Next Generation LNP Technology at International mRNA Health Conference
October 8, 2024 PUBLICATION ALERT: Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA Read about PUBLICATION ALERT: Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA
July 8, 2024 Christopher Sweeney Named Executive Director, Intellectual Property Read about Christopher Sweeney Named Executive Director, Intellectual Property
May 3, 2024 Acuitas Poster Presentations at ASGCT Annual Meeting Read about Acuitas Poster Presentations at ASGCT Annual Meeting
April 11, 2024 Acuitas Therapeutics Named One of Canada’s Top Small & Medium Employers of 2024 Read about Acuitas Therapeutics Named One of Canada’s Top Small & Medium Employers of 2024
February 13, 2024 Acuitas Therapeutics Named One of BC’s Top Employers of 2024 Read about Acuitas Therapeutics Named One of BC’s Top Employers of 2024
December 20, 2023 Acuitas Therapeutics’ Chief Legal Officer Miranda Lam Appointed as King’s Counsel Read about Acuitas Therapeutics’ Chief Legal Officer Miranda Lam Appointed as King’s Counsel
November 6, 2023 Dr. Ghania Chikh Named Senior Director, Vaccine Development at Acuitas Therapeutics Read about Dr. Ghania Chikh Named Senior Director, Vaccine Development at Acuitas Therapeutics
January 26, 2023 Acuitas Therapeutics’ President & CEO Named a National Winner in the EY Canadian Entrepreneur of the Year Program Read about Acuitas Therapeutics’ President & CEO Named a National Winner in the EY Canadian Entrepreneur of the Year Program